Richmond News Now

Chronic Kidney Disease (CKD) Market to Accelerate Substantially During the Forecast Period (2022-32) – DelveInsight | Key Companies – Akebia, FibroGen, Astellas, Tricida, Reata, Corvidia, AstraZeneca

 Breaking News
  • No posts were found

Chronic Kidney Disease (CKD) Market to Accelerate Substantially During the Forecast Period (2022-32) – DelveInsight | Key Companies – Akebia, FibroGen, Astellas, Tricida, Reata, Corvidia, AstraZeneca

November 08
17:50 2022
Chronic Kidney Disease (CKD) Market to Accelerate Substantially During the Forecast Period (2022-32) - DelveInsight | Key Companies - Akebia, FibroGen, Astellas, Tricida, Reata, Corvidia, AstraZeneca
Delveinsight Business Research LLP

As per DelveInsight, the Chronic Kidney Disease (CKD) therapeutics market is anticipated to increase in the coming years owing to the rising prevalent population in the 7MM, along with the expected entry of premium price assets such as Anti-inflammatories, Prolyl hydroxylase and IL-6 inhibitors.

DelveInsight’s “Chronic Kidney Disease (CKD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Kidney Disease market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Chronic Kidney Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Kidney Disease Market

Chronic Kidney Disease (CKD): An Overview

Chronic kidney disease (CKD) is a syndrome where there are persistent alterations in kidney structure, function, or both, with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations, and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, changes in output or quality of urine, and growth delay in children. These changes are most often recognized by increased serum creatinine levels, cystatin C, or blood urea nitrogen. Moreover, the most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis.

Several aspects must be considered when managing patients with CKD, including controlling further nephron injury, normalizing single-nephron hyperfiltration, controlling CKD-related complications, and preparing the patient for kidney replacement therapy. At the core of these is the principle of ‘the earlier, the better—an effort to reduce the progression to ESRD and optimize renal outcomes.

Chronic Kidney Disease (CKD) Market Key Facts

  • The total prevalent population of Chronic Kidney Disease (CKD) in the 7MM was 65,988,800+ in 2017.

  • Among the 7MM, the most prevalent cases of Chronic Kidney Disease (CKD) were recorded in the United States.

  • In the United States, the prevalent population of Chronic Kidney Disease (CKD) was 37,809,500+ in 2017.

  • Among the European 5 countries, Germany had the highest prevalent population of Chronic Kidney Disease (CKD), followed by France and the United Kingdom. On the other hand, Spain had the lowest prevalent population of CKD in 2017.

  • Among the 7MM, the second most prevalent cases of Chronic Kidney Disease (CKD) in 7MM were recorded in Japan, with 13,758,900+ cases in 2017.

Chronic Kidney Disease (CKD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Kidney Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Chronic Kidney Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Kidney Disease (CKD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Chronic Kidney Disease (CKD) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Kidney Disease market or expected to get launched during the study period. The analysis covers the Chronic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Chronic Kidney Disease (CKD) Market Will Evolve by 2032 @ 

https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Chronic Kidney Disease Therapeutics Analysis

The Chronic Kidney Disease Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment. Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.

Some of the key companies in the Chronic Kidney Disease Therapeutics Market include:

  • GlaxoSmithKline

  • Akebia Therapeutics

  • FibroGen

  • Astellas Pharma

  • AstraZeneca

  • Boehringer Ingelheim

  • Tricida

  • Reata Pharmaceuticals

  • Corvidia Therapeutics

And many others.

Chronic Kidney Disease Therapies covered in the report include:

  • Daprodustat

  • Vadadustat

  • Roxadustat

  • Empagliflozin

  • Dapagliflozin

  • Veverimer

  • Bardoxolone Methyl

  • Ziltivekimab

And many others.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More – 

https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Kidney Disease Competitive Intelligence Analysis

4. Chronic Kidney Disease Market Overview at a Glance

5. Chronic Kidney Disease Disease Background and Overview

6. Chronic Kidney Disease Patient Journey

7. Chronic Kidney Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Chronic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Kidney Disease Unmet Needs

10. Key Endpoints of Chronic Kidney Disease Treatment

11. Chronic Kidney Disease Marketed Products

12. Chronic Kidney Disease Emerging Drugs and Latest Therapeutic Advances

13. Chronic Kidney Disease Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Kidney Disease Market Outlook (In US, EU5, and Japan)

16. Chronic Kidney Disease Access and Reimbursement Overview

17. KOL Views on the Chronic Kidney Disease Market

18. Chronic Kidney Disease Market Drivers

19. Chronic Kidney Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

West Nile Encephalitis Market

“West Nile Encephalitis  Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the West Nile Encephalitis  Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/